X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA GLENMARK PHARMA PLETHICO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x -1.1 13.9 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PLETHICO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
GLENMARK PHARMA
Mar-16
PLETHICO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3951,262 31.3%   
Low Rs31672 4.7%   
Sales per share (Unadj.) Rs604.4270.6 223.4%  
Earnings per share (Unadj.) Rs32.524.9 130.6%  
Cash flow per share (Unadj.) Rs51.334.4 149.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs473.6151.3 312.9%  
Shares outstanding (eoy) m34.08282.16 12.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.6 9.9%   
Avg P/E ratio x6.638.9 16.9%  
P/CF ratio (eoy) x4.228.1 14.8%  
Price / Book Value ratio x0.56.4 7.0%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m7,262272,778 2.7%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m1,59613,782 11.6%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m20,59876,340 27.0%  
Other income Rs m386356 108.5%   
Total revenues Rs m20,98476,696 27.4%   
Gross profit Rs m2,81814,172 19.9%  
Depreciation Rs m6422,691 23.9%   
Interest Rs m1,5931,789 89.1%   
Profit before tax Rs m96910,048 9.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1383,028 -4.6%   
Profit after tax Rs m1,1077,019 15.8%  
Gross profit margin %13.718.6 73.7%  
Effective tax rate %-14.330.1 -47.4%   
Net profit margin %5.49.2 58.4%  
BALANCE SHEET DATA
Current assets Rs m18,87759,096 31.9%   
Current liabilities Rs m11,89640,018 29.7%   
Net working cap to sales %33.925.0 135.6%  
Current ratio x1.61.5 107.4%  
Inventory Days Days3675 47.9%  
Debtors Days Days198119 166.0%  
Net fixed assets Rs m9,86139,075 25.2%   
Share capital Rs m341282 120.7%   
"Free" reserves Rs m12,33130,281 40.7%   
Net worth Rs m16,13942,703 37.8%   
Long term debt Rs m4,70624,873 18.9%   
Total assets Rs m33,146111,026 29.9%  
Interest coverage x1.66.6 24.3%   
Debt to equity ratio x0.30.6 50.1%  
Sales to assets ratio x0.60.7 90.4%   
Return on assets %8.17.9 102.7%  
Return on equity %6.916.4 41.7%  
Return on capital %12.317.5 70.2%  
Exports to sales %21.443.3 49.4%   
Imports to sales %15.27.4 204.9%   
Exports (fob) Rs m4,40233,044 13.3%   
Imports (cif) Rs m3,1365,672 55.3%   
Fx inflow Rs m4,40236,945 11.9%   
Fx outflow Rs m3,18461,066 5.2%   
Net fx Rs m1,219-24,122 -5.1%   
CASH FLOW
From Operations Rs m2,4373,449 70.7%  
From Investments Rs m-6,265-8,802 71.2%  
From Financial Activity Rs m2,4906,986 35.6%  
Net Cashflow Rs m-1,337934 -143.2%  

Share Holding

Indian Promoters % 82.7 48.3 171.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 6.9 62.3%  
FIIs % 5.5 34.4 16.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.5 71.4%  
Shareholders   10,665 56,727 18.8%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS